Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CKD-391 vs Co-administered CKD-331 and D337 in Healthy Volunteers
NCT05634447Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin and ezetimibe in dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Primary Outcome Measure (Pharmacokinetics) at 72 hours. Started Dec 2022; status: completed.
02
Drugs
atorvastatinezetimibe
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT05634447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634447.